"Significant Progress Toward FDA Premarket Approval"

Sicys Bio announced on July 30 that it has successfully completed the first patient procedure in a pivotal clinical trial for 'Novosis Putty', its next-generation bone substitute, as part of the process for premarket approval (PMA) from the U.S. Food and Drug Administration (FDA).


Sicys Bio recently applied Novosis Putty during a transforaminal lumbar interbody fusion (TLIF) procedure for a patient with degenerative disc disease (DDD) at a spine specialty clinical institution in the United States. Patient enrollment is underway at around 30 spine specialty centers in both Korea and the United States, and the collected data is expected to serve as core clinical evidence for future regulatory approval applications.


'Novosis Putty' product. CGBio

'Novosis Putty' product. CGBio

View original image

Novosis Putty is a medical device featuring a sustained-release delivery platform, designed to gradually release bone morphogenetic protein (rhBMP-2) in alignment with the human bone healing process. The scaffold material itself serves as a bone graft substitute and is formulated as a putty that can be manually shaped as desired. It is designed to be stably positioned inside a cage, minimizing the risk of loss or migration of its components.



Hyunseung Yoo, CEO of Sicys Bio, stated, "We have successfully completed the first patient procedure with Novosis Putty in the United States, the world’s largest and most demanding medical device market. Following our exclusive North American commercialization partnership with DePuy Synthes, this achievement represents significant progress toward obtaining FDA premarket approval."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing